These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36084402)

  • 1. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
    Lopes Valentim Di Paschoale Ostolin T; Rodrigues Gusmão M; Augusto Siqueira Mathias F; Mirelle de Oliveira Cardoso J; Mendes Roatt B; Dian de Oliveira Aguiar-Soares R; Conceição Ruiz J; de Melo Resende D; Cristiane Fortes de Brito R; Barbosa Reis A
    Cell Immunol; 2022 Oct; 380():104592. PubMed ID: 36084402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
    Ostolin TLVDP; Gusmão MR; Mathias FAS; Cardoso JMO; Roatt BM; Aguiar-Soares RDO; Ruiz JC; Resende DM; de Brito RCF; Reis AB
    Vaccine; 2021 May; 39(20):2755-2763. PubMed ID: 33875268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
    Coler RN; Goto Y; Bogatzki L; Raman V; Reed SG
    Infect Immun; 2007 Sep; 75(9):4648-54. PubMed ID: 17606603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.
    de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC
    Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.
    Martins VT; Chávez-Fumagalli MA; Costa LE; Canavaci AM; Martins AM; Lage PS; Lage DP; Duarte MC; Valadares DG; Magalhães RD; Ribeiro TG; Nagem RA; Darocha WD; Régis WC; Soto M; Coelho EA; Fernandes AP; Tavares CA
    PLoS Negl Trop Dis; 2013; 7(3):e2148. PubMed ID: 23573301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.
    Lage DP; Machado AS; Freitas CS; Vale DL; Linhares FP; Cardoso JMO; Oliveira-da-Silva JA; Ramos FF; Pereira IAG; Ludolf F; Tavares GSV; Bandeira RS; Oliveira JS; Menezes-Souza D; Duarte MC; Galdino AS; Christodoulides M; Chávez-Fumagalli MA; Roatt BM; Martins VT; Coelho EAF
    Mol Immunol; 2023 Mar; 155():79-90. PubMed ID: 36731193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
    Ribeiro PAF; Vale DL; Dias DS; Lage DP; Mendonça DVC; Ramos FF; Carvalho LM; Carvalho AMRS; Steiner BT; Roque MC; Oliveira-da-Silva JA; Oliveira JS; Tavares GSV; Galvani NC; Martins VT; Chávez-Fumagalli MA; Roatt BM; Moreira RLF; Menezes-Souza D; Oliveira MC; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Cytokine; 2020 May; 129():155031. PubMed ID: 32062145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
    Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
    Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
    Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis.
    Martins VT; Lage DP; Duarte MC; Costa LE; Garde E; Rodrigues MR; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Acta Trop; 2016 Feb; 154():73-81. PubMed ID: 26593442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
    Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
    PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a CD4
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.
    Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA
    Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.